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Introduction
The prognosis in patients with pancreatic cancer is
poor and some authors describe it as a lethal disease.
At the time of diagnosis only 14% of patients could be
surgically treated and up to 30% of them die within 12
months [1]. Therefore, further clinical investigations
on preoperative patient qualification are needed. 
Serum carbohydrate antigen 19-9, the sialylated
Lewis blood group antigen defined by the monoclonal
antibody 1116 NS 19-9 (2), is a tumor-associated anti-
gen synthesized by normal pancreatic and ductal cells,
present in large quantities in normal pancreatic juice
[3]. CA 19-9 is considered to be the best serum mark-
er of pancreatic cancer due to its high sensitivity of 70-
90% and specificity of around 90% [4]. 
In the patients with pancreatic cancer, CA19-9 level
may depend on the increased production by pancreatic
cancer cells or by other cells of the affected region.
The concentration of the tumor marker CA 19-9 is
influenced by the patient's secretor status and Lewis
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genotype [5]. Therefore, the predictive value of CA 19-
9 may differ among different populations. Little is
known about the predictive value of the preoperative
serum CA 19-9 levels in patients with pancreatic cancer.
The aim of the study was to assess the value of the
preoperative plasma CA 19-9 level in determining
prognosis of the patients with pancreatic cancer, treat-
ed with a radical pancreatectomy.
Material and methods
Patients. Between 2000 and 2006, 92 patients with pancreatic cancer
underwent radical resection at the 2nd Department of General and
Oncological Surgery at Wroclaw Medical University in  Poland.  The
inclusion criteria to the study were the planned radical surgical
removal of the pancreatic tumor and absence of other malignancies.
The exclusion criteria included absence of histopathological confir-
mation of the pancreatic tumor, presence of distant metastases con-
firmed during operation, palliative surgery and absence of 5 year fol-
low-up after operation or follow-up until patient's death. 
A total of 81 patients were included into the study. The  profile
of study group is presented in Table 1. 
The plasma CA 19-9 and bilirubin concentrations were meas-
ured before surgery by an automated, commercially available
enzyme immunoassay in Axsym analyzer (Abott Diagnostics Lab-
oratory). A value of 37 U/ml was used as the upper limit of normal
levels.
Tumors were staged according to the Union Against Cancer
(UICC) of 2004 and graded during the histological evaluation
according to the G0-G4 scale.
Surgical treatment. The kind of surgical treatment depended on
location of the tumor. Whipple pancreatoduodenectomy in Traverso-
Longmire modification was performed for adenocarcinoma located
in pancreatic head. Distal pancreatoduodenectomy was performed
for tumors located in the body and tail of the pancreas. Resectabili-
ty was defined as tumor limited to the pancreas with no invasion of
the superior mesenteric vein and artery, portal vein and absence of
metastases (to coeliac lymph nodes, peritoneum or liver).
Adjuvant therapy. Adjuvant therapy was used in 70 patients
(chemotherapy in 63 and radiotherapy in 13 patients). The
chemotherapy protocols which were used are listed below: 
• Regimen A – gemcitabine 1000 mg/m2 iv on days 1, 8, 15; rest
period of 28 days between the cycles,
• Regimen B – gemcitabine 1000 mg/m2 iv on days 1, 8, 15 +
cisplatin 25 mg/m2 iv. on days 1, 8, 15; rest period of 28 days
between the cycles,
• Regimen C – calcium folinate 20 mg/m2 iv on days 1 – 5 + flu-
orouracil 300 mg/m2 iv. on days 1 – 5 (continuous infusion) +
cisplatin 20 mg/m2 iv. on days 1 – 5 (continuous infusion); rest
period of 28 days between the cycles,
• Regimen D- fluorouracil 500 mg/m2 iv on days 1 – 5; rest peri-
od of 28 days between the cycles.
The type of protocol, in each patient ,was assigned by the
oncologist on the basis of individual  assessment.
Follow-up. All patients were monitored every three month via out-
patient clinic visits. In the case of missing visit we contacted the
families to establish the cause.
The patients were divided into groups according to their out-
come: death during the perioperative period, death in postoperative
period till 12 months follow up, survival longer than 12 months.
Survival analysis.
We assessed perioperative, 12 month, 2 year and 5 year survival.
Twelve moth, 2 year and 5 year survival were assessed in the
whole studied population and in the group of patients with the
exception of these who died during the perioperative period.
Statistical analysis.
Continuous variables were presented as means and their stan-
dard deviation or median and interquartile range, according to their
distribution.  
Categorical variables were presented as numbers and percentages.
All continuous data were dichotomized around the median
value or according to significant cut-off points.
We performed ROC curve analyses to find the serum CA19-9
levels which could have predicted survival to hospital discharge,
12 month survival, 2 year survival 
Preoperative CA 19-9 concentrations were dichotomized
according the value calculated by means of ROC curve analyses.
For the purposes of statistical analyses the categorical vari-
ables, such as tumor size, grade, location were linked to obtain
two categories of patients in respect to a given parameter on the
basis of the comparison of their distribution in studied groups.
For 12 month and 2 year survival we also performed analysis
after excluding the patients who died during perioperative period
because their survival could be related to other factors than pan-
creatic cancer.
Statistical analysis. Survival probability was estimated according
to Kaplan-Meier method, the log rank test was used to compare
survival in different subgroups. Multivariate analyses were per-
formed using Cox's proportional hazard model or logistic regres-
sion analysis. P values less than 0.05 were considered significant.
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Table 1. Characteristics of the studied group of patients.
Results
Overall survival
The total five year survival was 6%. The median time
of survival was 467 days (range: 163 – 586 days). The
perioperative period was survived by 91.4% patients,
12 months were survived by 71.6% patients, 2 years
were survived by 35.8% patients, 5 years were sur-
vived by 6.2% patients.
Out of the 45 men and 36 women included into the
analyses 7 patients ( 5 men and 2 women) died during
the perioperative period (perioperative death – PD).
Out of the 40 men and 34 women who were dis-
charged alive from hospital, 16 patients (11 men, 5
women) died during the 12 month follow-up after the
surgery (early death – ED).
Out of the remaining 58 patients (29 men and 29
women), 5 patients (3 men, 2 women) survived 5-year
follow-up and 53 patients (26 men, 27 women) died
during the follow-up.
The clinical, histopathological and biochemical
characteristics of the patients divided into groups
according to the time of survival are shown in Table 2
and 3.
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Table 2. Demographics, histological characteristics and biochemical data in studied population divided into groups of various survival time.
ED or 1Y-S vs PD *p<0.05                                                   1Y-S vs ED: # p<0.05  ##-A -p<0.01 T1+T2+T3 vs T4 ##-B-p<0.01 IA+IIA+IB vs IIB p<0.01
Serum CA 19-9 level
The serum Ca 19-9 level was above the normal limit in
80.5% patients. 
ROC curve analysis revealed that CA 19-9 level of
more than 106 U/ml was linked to 2 year survival with
79.3% sensitivity and 74.5% specificity. Twelve month
survival and survival to hospital discharge could not be
predicted by CA 19-9 level (Tables 1, 2, 3).
CA 19-9 level, both as a continuous variable and
dichotomized, as at least 106 U/ml or more than 106
U/ml, was an independent predictor of overall survival,
2 year survival but it was not related to perioperative
death (Table 4-11). Survival analysis during the first 12
months showed that the higher level of CA 19-9 was
linked to the higher risk of death in the whole analyzed
group, but such a relationship could not be detected
when the subgroup of patients who died during the peri-
operative period was excluded (Table 7-12). 
In the Fig. 1-3 the results of ROC curve analysis of
the serum CA 19-9 in prediction of the perioperative,
12 month and 2 years survival were presented.
Bilirubin
Serum bilirubin did not correlate with CA 19-9 level
but it was significantly higher in patients with higher
T, N stages, G grades.
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Table 3. Demographics, histological characteristics and biochemical data in studied patients who survived for more than 12 months 
Serum bilirubin of no more than 12.1mg% could
predict 2 year survival with low sensitivity and a rela-
tively high specificity (Fig. 4, Table 4).
The ROC analysis showed no relationship between
the level of bilirubin and the perioperative and 12-
month period deaths. Thus, for further analysis the
dichotomized variable of bilirubin level was used, high-
er or lower than that obtained for 2 year survival. Serum
bilirubin as a continuous variable was not independent-
ly related to overall survival, 2 year survival, 12 month
survival (Table 7-12) but when dichotomized its higher
level was related to death during the perioperative peri-
od (OR 8.3, CI 1.5- 48.4; p<0.001).
Adjuvant therapy
In 63 patients chemotherapy and in 13 patients radio-
therapy was used as the adjuvant therapy. Both the
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Fig. 1. ROC curve analysis of preoperative Ca 19-9
level for the prediction death before hospital discharge.
Fig. 2. ROC curve analysis of preoperative Ca 19-9
level for the prediction 12 month survival.
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Fig. 3. ROC curve analysis of preoperative Ca 19-9
level for the prediction 2 year survival.
Fig. 4. ROC curve analysis of plasma bilirubin level in
predicting 2 year survival.
Table 4. Logistic regression analysis, prognostic factors associated with perioperative death.
methods were used post-operatively, hence in 7
patients who died in the peri-operative period no adju-
vant therapy was used. From among the 74 patients
who survived to hospital discharge in 4 patients no
adjuvant therapy was used due to lack of approval by
the oncologist or patient's refusal.
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Table 5. Multiple logistic regression analysis, prognostic factors
significantly associated with 12-month mortality in the group of
patients who were discharged alive from hospital. 
Table 8. Cox's proportional hazard model: prognostic factors related to 12 month survival in the studied population following exclusion
of patients who died in periprocedural period.
Table 6. Multiple logistic regression analysis, prognostic factors significantly associated with 2-year mortality in the group of patients
who were discharged alive from hospital. 
Table 7. Cox's proportional hazard model prognostic factors related to 12 month survival.
Patients who underwent chemotherapy differed sig-
nificantly in respect to T stage in comparison to the
population in whom no chemotherapy was used.. Che-
motherapy was used in 6 patients with T1 stage, in 31
patients with T2 stage and 26 patients with T3 stage
cancer; whereas it was not used in 8 patients with T1
stage, 2 patients with T2  and 1 patient with T3 stage
(p<0.001). Radiotherapy was used in 13 patients
among which 11 patients with T1 and 2 patients with
T2 and it was not used in 3 patients with T1, 31
patients with T2 and 27 patients with T3 stage. Patients
in whom radiotherapy was used differed from those in
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Table 9. Cox's proportional hazard model, prognostic factors related to 2 year survival.
Table 10. Cox's proportional hazard model, prognostic factors related with 2 year survival in the studied population following exclusion
of the patients who died in periprocedural period.
Table 11. Cox's proportional hazard model, prognostic factors related to 5 year survival.
whom radiotherapy was not used in respect to T stage
distribution (p<0.001) 
Four methods of chemotherapy were used as
described above: regimen A in 17 patients, regimen B
in 13 patients, regimen C in 10 patients and regimen D
in 23 patients.
Analysis of survival 
Overall mortality was independently related to N1,
male gender, CA 19-9 level (Tables 11, 12).
After exclusion of the PD group, five year survival
was related to N1, male gender, CA 19-9 level and also
to T3 (Tables 10, 11).
In patients who survived till the hospital discharge,
two year mortality was independently related to CA
19-9 level above 106 mU/ml, T3, G3, age above 65
years, male gender (Tables 8, 9).
In patients who survived till the hospital discharge
twelve month mortality was related only to N1.
(Table 7-8)
Perioperative death was related to bilirubin level
and older age of the patients (Table 4).
Overall survival in the group according to the CA
19-9 level was presented in the Fig. 5.
The influence of the adjuvant therapy on the long
term survival was assessed only in patients who sur-
vived to hospital discharge after surgery. Overall sur-
vival in groups treated and no treated with chemother-
apy and radiotherapy were presented in Fig. 6 and 7.
In univariate and multivariate Cox proportional
hazards regression both chemotherapy and radiothera-
py were not independent factors affecting 12 months
survival, 2 years survival and 5 year survival. (Figs 6,
7, Tables 8, 10, 12) Additionally, no relation was found
with the chemotherapy regimen.
Discussion
The overall prognosis associated with carcinoma of
the pancreas has not  improved over the last 20 years,
even if new diagnostic and therapeutic strategies have
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Table 12. Cox's proportional hazard model, prognostic factors related to 5 year survival in the studied population following exclusion of
patients who died in periprocedural period.
Table 13. Results of till now published studies on CA 19-9 level in groups of specific advancement in pancreatic neoplasia.
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Fig. 5. Overall survival in the group according to the CA 19-
9 level.
Fig. 6. Overall survival in the group
according to chemotherapy using
(p=NS).
Fig. 7. Overall survival in the group according
to radiotherapy using (p=NS).
appeared [6,7]. Radical pancreatectomy is the only
method which enables long term survival but quite
often in cases of potentially operable pancreatic tumor
the cancer has already spread outside of the pancreas
and long-term survival is impossible. Surgical treat-
ment may be a risky procedure, it worsens the quality
of life and may shorten the life expectancy. Thus,
investigations on predictive factors in pancreatic can-
cer are needed. These factors should have predictive
value in relation to longer survival after surgery than
after palliative treatment. Tumor characteristics (tumor
size, lymph node metastases, histologic differentia-
tion) and post-surgery blood transfusion are the estab-
lished predictors of survival [8]. The value of CA 19-9
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Table 14. Results of till now performed studies on predictive significance of CA 19-9 level in patients with pancreatic carcinoma.
levels as a prognostic factor in pancreatic cancer has
not been established yet. Higher levels of CA 19-9
have been found to be associated with more advanced
cancer, as expressed by tumor size and lymph node,
peritoneal and liver metastases (Table 13). According
to other studies, lower CA 19-9 levels have been found
to be associated with longer survival (Table 14) but no
unambiguous cut-off value of CA19-9 has been estab-
lished for presence or absence of the long-term risk,
ranging in various studies between 37 U/ml and 1000
U/ml.
We have found that CA 19-9 serum level before
surgery could have been taken as a prognostic factor
for 2 and 5 year survival, independent from other fac-
tors like tumor size, lymph node metastasis, age. Our
results are consistent with other publications on this
topic (Table 14).
The main result of our study is that CA19-9 level
not higher than 106 U/ml is connected with survival of
at least 2 years with relatively high specificity and sen-
sitivity in patients with pancreatic cancer treated with
radical pancreatectomy, chemotherapy and radiothera-
py. In other publications on this topic, longer survival
was connected with higher CA 19-9 levels, but the cut-
off point was established arbitrarily or on the level of
its median value. In our study, the CA 19-9 level
accepted as the cut-off point has been established as a
result of statistical analysis of specificity and sensitiv-
ity of 2 years survival upon  acceptance of different
cut-off points using ROC method.
No relationship has been identified between the
preoperative CA 19-9 level and deaths in the first year.
An elevated CA 19-9 level may be caused by an
increased expression of sialyated proteins on cancer
cells which may mark their higher metastatic potential
and the presence of metastases which have not been
identified  during routine imaging studies. On the other
hand, high CA 19-9 levels may be an unspecific reac-
tion of bile duct cells to cancer or inflammation.
Inflammatory response is also activated in pancreatic
cancer, thus high platelet and C-reactive protein levels
can be observed [22,23]. The lack of relationship
between one-year mortality and preoperative CA 19-9
levels argues against the hypothesis that its elevated
levels represents an exponent of metastases which
have not been identified:  if they were present, the sur-
vival time would be very short and, thus, one-year
mortality should be higher. It cannot, however, be
excluded, that an elevated preoperative CA 19-9 level
in cases of a resectable tumor reflect presence of
micrometastases, which activate the inflammatory
response and lead to an increase in CA 19-9 production
in non-cancerous bile duct cells.
In our study group the perioperative mortality has
amounted to 8.6% and has been similar to observations
of other authors. Up to now, in most of the studies the
perioperative mortality was related to the course of
operation, higher blood loss, longer time of operation.
We have found that patients who did not survive the
operation had significantly higher CA 19-9 levels than
patients who survived at least one year. In ROC analy-
sis we have found that the trend can be noted toward
the perioperative deaths upon CA 19-9 levels of at
least 315 U/ml.
Our results support the opinion that radiotherapy
and chemotherapy has only small effect on the survival
in patients with pancreatic cancer and that only an
early radical surgery increases the survival time. 
Conclusions
Preoperative level of CA 19-9 below 106U/ml repre-
sents a  predictive factor of  2- and 5-year survival,
independent of other factors, such as lower size of the
tumor, absence of metastases to lymph nodes, female
gender of patients. After exclusion of the patients who
died in the perioperative period, no relationship could
have been disclosed between preoperative CA 19-9
levels and one year survival. The observation points to
the chance that patients with higher levels of CA 19-9
harbour micrometastases, the development of which is
sufficiently slow to allow for a one-year survival of the
patients but which increase the risk of death after two
and five years. A markedly elevated preoperative level
of CA 19-9 may point to the local advancement of the
neoplastic lesion, making the surgical procedure more
difficult and, therefore, increasing periprocedural mor-
tality. The hypothesis requires verification by further
investigations. 
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